🔗 Share this article

A shadow market for unapproved weight-loss drugs is being driven by social media fitness personalities and vendors on communication apps, based on new investigations.

Experimental Drug Gaining Popularity Online

Retatrutide, which remains in clinical trials, is being advertised by social media influencers for its supposed fat-burning effects. Viewers are encouraged to message these accounts privately for supplier links, while also receiving discount codes.

Thriving Trade on Messaging Platforms

Separately, a flourishing trade exists on messaging services, where communities with thousands of participants share comparison images, administration instructions and claims of rapid UK delivery. Vendors promote the drug there before redirecting buyers to WhatsApp for transactions.

Understanding The Experimental Drug

This medication is an experimental injectable created by American pharmaceutical company Eli Lilly. The drug affects three gut hormones – GLP-1, GIP and pancreatic hormone. Preliminary studies suggest it could assist patients reduce up to 25% of their body weight. Referred to as the “triple G”, the drug is being promoted digitally as the next Ozempic.

Healthcare Experts Voice Worries

Nevertheless, doctors and chemists have cautions that the sale of what remains an unlicensed drug in the UK is a cause for concern and could lead to users injecting products of uncertain source.

Some professionals said the demand for the experimental drug could be linked to the increasing price of licensed weight loss products such as Mounjaro.

Regulatory Position and Implementation

Selling the unapproved drug on social media or messaging apps is illegal in the UK, as it is an unlicensed medication that cannot be promoted or distributed for human use under the Human Medicines Regulations 2012.

Some content creators try to circumvent the rules by referring to the drug as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a controlled substance, but promotion and distribution can still violate pharmaceutical, advertising, and consumer laws, potentially leading to fines, legal action or prison.

Platform Response and Material Removal

According to the social media company, the platform has removed problematic content and banned related hashtags and query recommendations. The company stated it was committed to keeping the service safe and allocating resources in enhancing compliance measures.

Online Trading Operations

Investigations also found groups with up to 9,000 members selling retatrutide using the platform's integrated search feature, which operates like a public directory. Entering “retatrutide” immediately displays groups with thousands of users, populated with photos of slimming results, positive testimonials and detailed instructions for preparing or administering at home.

After moments of joining one community, a seller shared contact information, where most transactions occur. The vendor sent an instruction manual and guaranteed delivery within two days. When questioned whether the substance was authentic, one seller responded: “You can’t be sure.” Another provided a image of a supposed laboratory certificate. Not one asked about weight, medical conditions or past usage.

Item Information and Pricing

Inside these communities, posts display black plastic packages with Royal Mail stickers, claiming to include new batches. One communication read: “It took eight of us to load them this morning.”

Buyers can select between dry substance containers, prepared at home with sterile water, or pre-filled injectors usually sold at 160 pounds for 20mg. When asked how long a pen should be used, sellers give conflicting answers ranging from a several days to “depends on your body”.

Platform Oversight and Security Actions

A spokesperson for Telegram said it actively moderated dangerous content on its service including material that promoted the “misuse of controlled medications”. The organization added that it eliminated “millions of pieces of harmful content each day”.

Healthcare Expert Cautions

“Individuals are injecting materials they can’t verify. Even if the research behind this drug is sound, these digital versions may not include what they advertise,” said Jason Murphy, the head of pharmaceutical services at Chemist4U.

A medical professional of an online medical service connected the increase in demand to current cost increases for authorized weight-loss medications such as Mounjaro. “With prices increasing, individuals are using online platforms. But counterfeit treatments are extremely risky. You can’t be certain what’s inside or whether the environment they were produced in was sterile,” she said.

Her staff has previously encountered patients harmed by personal administration from unverified sources. “We understand the disappointment, but buying from Telegram or communication platforms is gambling with your health,” said the doctor. “These substances could be impure or incorrectly dosed.”

Producer Statement

A spokesperson from the pharmaceutical company stated retatrutide was in third stage research studies and had not been evaluated or authorized by any government authority globally. “Consequently at this time no one can sell [it] for personal consumption,” they explained, noting that any product “falsely representing itself as a Lilly investigational product not yet approved … may subject patients to potentially serious medical dangers”.